Skip to main content

Adalimumab FDA Approved for Hidradenitis Suppurativa

Sep 14, 2015 7:52 am

Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.

Approval is based on the results of two pivotal Phase 3 studies, PIONEER I and PIONEER II, that included 633 people with moderate to severe HS. Both studies showed that adalimumab significantly reduced the total number of abscesses and inflammatory nodules compared with patients given placebo. No new safety risks were identified in these trials.

The European Commission approved adalimumab for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic treatment.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists’ Comments

Ladislas Lazaro IV

| Sep 14, 2015 10:10 pm

I have treated a 58 y/o gentleman with Hydroadenitis associated arthritis using Inflixamab for approximately 8 years now. Excellent response of the arthritis and near complete resolution of skin lesions. Occasional mild skin lesion if infusion is delayed, which occurs due to pts. schedule, however, through the years there has been absolutely no need further surgical intervention regarding the Hydroadenitis. Prior to biological therapy, he frequently required surgical abscess resection, and just prior initiation of Inflixamab therapy, had a complete axillary dissection.

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.